Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
| ▸ | CTH | P32929 | 1/20 | 0.31 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.31 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421124 | 0.77 | ALDH1A1 (0.40) | GLRA1SLC6A9OR51E2KDM4EMAPT | |
| SCHEMBL27847024 | 0.72 | KDM4E (0.44) | GLRA1SLC6A9OR51E2KDM4EMAPT | |
| SCHEMBL1407278 | 0.70 | — | — | |
| SCHEMBL28738431 | 0.70 | — | — | |
| SCHEMBL6677007 | 0.70 | ABCC4 (0.42) | MAPTLMNA | |
| SCHEMBL94667 | 0.70 | KDM4E (0.43) | GLRA1SLC6A9OR51E2KDM4EHIF1A | |
| Ammonia Solution, Strong SCHEMBL5722441 | 0.69 | KDM4E (0.41) | GLRA1SLC6A9OR51E2KDM4EHIF1A | |
| SCHEMBL6826958 | 0.68 | LDHA (0.33) | GLRA1SLC6A9OR51E2LDHASRR | |
| Hydrochloric Acid SCHEMBL2310467 | 0.68 | KDM4E (0.41) | GLRA1SLC6A9OR51E2KDM4EMAPT | |
| SCHEMBL5529534 | 0.67 | HMGCR (0.35) | GLRA1SLC6A9OR51E2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3341364-B1 | PROCESS FOR THE PREPARATION OF A DUAL-ACTING ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR COMPOUND | HETERO LABS LTD (IN) | 2023-12-20 | — | — | EP | disclosed |
| US-10822314-B2 | Process for the preparation of a dual-acting angiotensin receptor-neprilysin inhibitor compound | HETERO LABS LTD. (IN) | 2020-11-03 | — | — | US | disclosed |
| US-10562867-B2 | Process for the preparation of a dual-acting angiotensin receptor-neprilysin inhibitor compound | HETERO LABS LTD. (IN) | 2020-02-18 | — | — | US | disclosed |
| US-20200048210-A1 | PROCESS FOR THE PREPARATION OF A DUAL-ACTING ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR COMPOUND | HETERO LABS LTD. (IN) | 2020-02-13 | — | — | US | disclosed |
| US-20190112278-A1 | PROCESS FOR THE PREPARATION OF A DUAL-ACTING ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR COMPOUND | HETERO LABS LTD. (IN) | 2019-04-18 | — | — | US | disclosed |
| US-20190070136-A1 | PARENTERAL COMPOSITIONS OF CARMUSTINE | ASPIRO PHARMA LIMITED (IN) | 2019-03-07 | — | — | US | disclosed |
| US-20180244636-A1 | PROCESS FOR THE PREPARATION OF A DUAL-ACTING ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR COMPOUND | HETERO LABS, LTD. (IN) | 2018-08-30 | — | — | US | disclosed |
| EP-3341364-A1 | PROCESS FOR THE PREPARATION OF A DUAL-ACTING ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR COMPOUND | Hetero Labs Ltd. (IN) | 2018-07-04 | — | — | EP | disclosed |
| US-20170304451-A1 | PARENTERAL COMPOSITIONS OF BENDAMUSTINE | HETERO RESEARCH FOUNDATION (IN) | 2017-10-26 | — | — | US | disclosed |
| WO-2017037591-A1 | PROCESS FOR THE PREPARATION OF A DUAL-ACTING ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR COMPOUND | HETERO RESEARCH FOUNDATION (IN) | 2017-03-09 | — | — | WO | disclosed |
| EP-1599550-B1 | CATIONIC DYES, THEIR PRODUCTION AND USE | BASF SE (DE) | 2010-01-27 | — | — | EP | disclosed |
| US-7482438-B2 | Cationic imidazolazo dyes containing a 2,5-diaminophenyl moiety | CIBA SPECIALTY CHEMICALS CORP. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070214580-A1 | Cationic Imidazolazo Dyes Containing A 2,5-Diaminophenyl | CIBA SPECIALTY CHEMICALS CORP. | 2007-09-20 | — | — | US | disclosed |
| US-7258702-B2 | Yellow cationic dyes for dyeing of organic material | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1483334-B1 | PROCESS FOR EXCHANGING THE ANIONS OF CATIONIC DYES | CIBA SC HOLDING AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| US-7166710-B2 | Cationic dimeric dyes | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166711-B2 | Cationic dyes | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2007-01-23 | — | — | US | disclosed |
| US-7091358-B2 | Cationic substituted hydrazone dyes | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20050120493-A1 | Process for exchanging the anions of cationic compounds | CIBA SPECIALTY CHEMICALS CORP. | 2005-06-09 | — | — | US | disclosed |
| US-20050000034-A1 | Yellow cationic dyes for dyeing of organic material | CIBA SPECIALTY CHEMICALS CORPORATION | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050120493-A1 | Process for exchanging the anions of cationic compounds | SLC10A6, SLC43A1, SLCO4C1 | GLRA1 2438/4885SLC6A9 45/4885OR51E2 272/4885 |
| US-20170304451-A1 | PARENTERAL COMPOSITIONS OF BENDAMUSTINE | FOLR1, FOLR2, PAICS | GLRA1 3159/4885SLC6A9 1016/4885OR51E2 4454/4885 |
| US-20050000034-A1 | Yellow cationic dyes for dyeing of organic material | KRT18, PYCR1, CYC1 | GLRA1 2948/4885SLC6A9 3784/4885OR51E2 1550/4885 |
| US-20200048210-A1 | PROCESS FOR THE PREPARATION OF A DUAL-ACTING ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR COMPOUND | AGTR2, AGTR1, MME | GLRA1 1850/4885SLC6A9 255/4885OR51E2 2925/4885 |
| US-20190070136-A1 | PARENTERAL COMPOSITIONS OF CARMUSTINE | PAICS, MGMT, NRAS | GLRA1 784/4885SLC6A9 311/4885OR51E2 3577/4885 |
| US-20180244636-A1 | PROCESS FOR THE PREPARATION OF A DUAL-ACTING ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR COMPOUND | AGTR2, AGTR1, MME | GLRA1 1850/4885SLC6A9 255/4885OR51E2 2925/4885 |
| US-10562867-B2 | Process for the preparation of a dual-acting angiotensin receptor-neprilysin inhibitor compound | AGTR2, AGTR1, MME | GLRA1 1850/4885SLC6A9 255/4885OR51E2 2925/4885 |
| US-20190112278-A1 | PROCESS FOR THE PREPARATION OF A DUAL-ACTING ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR COMPOUND | AGTR2, AGTR1, MME | GLRA1 1850/4885SLC6A9 255/4885OR51E2 2925/4885 |
| US-10822314-B2 | Process for the preparation of a dual-acting angiotensin receptor-neprilysin inhibitor compound | AGTR2, AGTR1, MME | GLRA1 1850/4885SLC6A9 255/4885OR51E2 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.